Genospace Partner Sequence Bio Announces Initiative with Government of Newfoundland and Labrador on Large-Scale Precision Medicine Initiative
CAMBRIDGE, MA — Genospace, a precision medicine software company that has developed a comprehensive suite of tools enabling the broad use of genomic and other biomedical data in research and clinical care, today announced that Sequence Bioinformatics, Inc. and the Government of Newfoundland and Labrador have selected Genospace Population Analytics™ to support a groundbreaking precision medicine initiative.
Sequence Bio, in partnership with the Government of Newfoundland and Labrador, seeks to engage 100,000 consenting participants in a large-scale initiative to capture a wealth of genomic and phenotypic data. The initiative will make the resulting information and analysis available to a variety of organizations in order to improve patient care.
“The Newfoundland and Labrador population is a unique resource for genetic investigation of complex diseases,” said Mick Correll, co-founder and chief executive officer of Genospace. “The province’s collaboration with Sequence Bio takes a community-based approach to apply the latest genomic technologies to advance data-driven precision medicine. We are excited to power this important initiative.”

